Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified DexCom ( DXCM) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified DexCom as such a stock due to the following factors:
- DXCM has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $36.2 million.
- DXCM has traded 11,395 shares today.
- DXCM is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in DXCM with the Ticky from Trade-Ideas. See the FREE profile for DXCM NOW at Trade-Ideas More details on DXCM: DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 8 analysts that rate DexCom a buy, no analysts rate it a sell, and 5 rate it a hold. The average volume for DexCom has been 630,400 shares per day over the past 30 days. DexCom has a market cap of $3.0 billion and is part of the health care sector and health services industry. The stock has a beta of 0.20 and a short float of 5.8% with 4.24 days to cover. Shares are up 20.2% year-to-date as of the close of trading on Thursday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates DexCom as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Highlights from the ratings report include:
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, DEXCOM INC's return on equity significantly trails that of both the industry average and the S&P 500.
- DEXCOM INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, DEXCOM INC reported poor results of -$0.79 versus -$0.68 in the prior year. This year, the market expects an improvement in earnings (-$0.47 versus -$0.79).
- The gross profit margin for DEXCOM INC is rather high; currently it is at 68.30%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -13.98% is in-line with the industry average.
- Net operating cash flow has significantly increased by 126.44% to $1.60 million when compared to the same quarter last year. In addition, DEXCOM INC has also vastly surpassed the industry average cash flow growth rate of -27.73%.
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 65.2% when compared to the same quarter one year prior, rising from -$17.26 million to -$6.00 million.
- You can view the full DexCom Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.